Medical device company Medical Developments International (ASX:MVP) has successfully raised $20 million from institutional investors as part of their plans to raise a total of $30 million to fund global expansion plans for its flagship non-opioid painkiller, Penthrox (aka the Green Whistle). Capital raised at the Offer Price of $2.00 per share will be used to
Read More
Modern medicine is akin to magic, a notion exemplified when looking at the regenerative power of stem cells. Whilst we’ve barely scraped the surface of what these powerful cells can do, regenerative medicine holds promise as a “magic fix” for many an ailment. Clinical stage regenerative medicine company Regeneus (ASX: RGS) is working to develop
Read More
“How much does it hurt, on a scale of 1-10?” Easily the most frustratingly vague of medical questions due to the huge difference in pain thresholds and perceptions. I don’t know about you, but I’m saving my 10 for childbirth. Nonetheless, when the answer falls beneath an epidural-requiring 10, many of us reach for simple
Read More
While prescription opioids have been getting a pretty bad rap over the past few years amid revelations in the US about a certain Sackler family, they still have a vital role to play in healthcare where good guys like Palla Pharma (ASX: PAL) have strengthened their balance sheet with the sale of their manufacturing facility
Read More
Pain management is one of the most fascinating arms of medicine. Post-operative pain management, even more so. Practitioners must strike a balance to ensure that acute pain doesn’t turn into chronic pain, and that a patient’s dependence on analgesia is temporary. The many issues with opioid based pain medications are well documented and, with a
Read More
The commercialisation of osteoarthritis treatment ZILOSUL® has hit a hiccup in the United States with the US Food and Drug Administration (FDA) raising fresh questions to late-stage drug development company, Paradigm Biopharmaceuticals (ASX: PAR). The FDA response related to Paradigm’s application for Investigational New Drug status to be granted for their focus compound, Pentosan Polysulfate
Read More